Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)

Next Previous
X
Search
Trial Profile

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MAGNIFY; MAGNIFY-MS
  • Sponsors Merck KGaA

    • Most Recent Events

    • 12 Sep 2024 Results published in the EMD Serono Media Release
    • 12 Sep 2024 Results of two-year data from MAGNIFY-MS sub-study published in a Merck media release
    • 12 Sep 2024 According to a Merck media release, data from several MAGNIFY-MS sub-studies demonstrating the impact of MAVENCLAD on disability progression, central inflammation, will be presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place Sept 18-20 in Copenhagen.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top